93. Primary biliary cholangitis Clinical trials / Disease details
Clinical trials : 298 / Drugs : 252 - (DrugBank : 59) / Drug target genes : 35 - Drug target pathways : 115
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs051210210 | 30/03/2022 | 30/03/2022 | BIG STEP | Benefit of glucosyl Hesperidin in patients with primary biliary cholangitis: amulticenter, open-label, randomized control study | Primary Biliary Cholangitis Cholangitis | Participants will be randomly assigned to standard dose and high dose groups. In standard dose group, hesperidin tablet 500 mg (two tablets at a time once a day after meal) will be orally administered for 24 weeks. In high dose group, hesperidin tablet 1000mg (four tablets at a time once a day after meal) will be orally administered for 24 weeks. | Fujinaga Hisayuki | NULL | Recruiting | >= 20age old | Not applicable | Both | 110 | Phase 2 | Japan |